Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Hadean Ventures
BioCentury | Jul 12, 2024
Finance
Venture Report: With more company creation on tap, Flagship raises $3.6B
Plus: Big rounds for Element, Beacon and Myricx
BioCentury | May 4, 2023
Finance
May 3 Quick Takes: Clinical-stage targeted radio-antibody newco Convergent raises $90M A round
Plus: Big gain for ImmunoGen as Elahere hits mark in confirmatory study and updates from Cowen, Longwood, Morphic, Arthex and Dianthus
BioCentury | Apr 17, 2023
Emerging Company Profile
Complement: taking on Apellis with a gene therapy for geographic atrophy
New target CR1 could shut down complement signaling more fully than Apellis’ C3-targeted therapy
BioCentury | Dec 15, 2022
Emerging Company Profile
Ribbon: high-throughput enzymatic assembly of long DNA molecules
Vienna-based Ribbon aims to reduce a bottleneck in the development of biologics
BioCentury | Feb 22, 2022
Emerging Company Profile
TargED: targeting thrombotic disorders directly at clotting sites
Dutch start-up with about €40M in funding will advance fusion protein targeting von Willebrand factor for two indications
BioCentury | Feb 2, 2022
Deals
Feb. 1 Quick Takes: Investors skeptical of Anavex’s Phase III success
Plus Merck brings tau mAb to clinic, ethris and Ribbon Biolabs raise venture rounds, and more
BioCentury | Dec 7, 2021
Emerging Company Profile
Emergence: creating better ADCs for Nectin-4
German start-up raises €87M series A as it seeks to improve upon Seagen’s Padcev
BioCentury | Aug 26, 2021
Finance
Cardior’s €64M B round to push first-in-class heart failure program into Phase II
German company’s goal is disease-modification, a sign of lead investor Inkef Capital’s growing ambition in life sciences.
BioCentury | Mar 24, 2021
Finance
With cancer foot forward, Step making strides toward clinic with €35M series B
French biotech considering accelerated pathway for lead program
BioCentury | Jul 10, 2020
Finance
With an eye on ‘underserved’ Nordic biotechs, Eir raises €76M toward first fund
The new firm believes Scandinavia offers high-quality science in a market with few dedicated VCs
Items per page:
1 - 10 of 14